Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

NCT00168012 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Agammaglobulinemia
IgG Deficiency
Common Variable Immunodeficiency

Interventions

DRUG: Immunoglobulins Intravenous (Human)

Sponsor

CSL Behring